... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hyperprolactinemia Pituitary tumor Dopamine agonists Bromocriptine Cabergoline Lisuride Pergolide Quinagolide Indications for therapy in patients...

... bromocriptine (BC), but not DA, is initiated through activation of the JNK pathway. However, both DA and BC activate the terminal effector caspase, caspase-3. Kinetic studies and chemical inhibitor co-incubation experiments support a role for JNK activation preceding caspase-9 activation in BC challenged cells...

...Lisa M. Davis; Michael Michaelides; Lawrence J. Cheskin; Timothy H. Moran; Susan Aja; Paul A. Watkins; Zhengtong Pei; Carlo Contoreggi; Karen McCullough; Bruce Hope; Gene Jack Wang; Nora D. Volkow; Panayotis K. Thanos Background: The dopamine (DA) D 2 receptor (D2R) agonist bromocriptine (BC...

... of male rats. During selective inhibition of the AL or IL by pretreatment with dexamethasone (Dx) or bromocriptine (Br), respectively, we studied the effect of equipotent doses of intracerebroventricularly infused HA, the H 1 -receptor agonist 2-thiazolylethylamine (2TEA) or the H 2 -receptor agonist 4...

... days. The purpose of this study was to investigate whether hypothalamic dopaminergic (DA) systems acting through D 2 receptors may be involved in this melatonin-induced effect. Groups of Soay rams living under long days were treated in the MBH with micro-implants containing bromocriptine (BROM, DA D 2...

...Laure Caccavelli; Francois Feron; Isabelle Morange; Evelyne Rouer; Richard Benarous; Didier Dewailly; Phillipe Jaquet; Claude Kordon; Alain Enjalbert Bromocriptine or other dopamine agonists are usually effective for the treatment of prolactin-secreting adenomas. Five to 18% of prolactinomas...

... pituitaries. Such in vitro sex differences in LH release were not due to higher in vitro prolactin release by female than male pituitaries as suppression of pituitary prolactin secretion by perifusion with the dopamine agonist bromocriptine failed to erase sex differences. Since GnRH pulse frequency in vivo...

... weeks. Counts by light microscopy of apoptotic cells and cells containing phagocytosed apoptotic bodies increased during a period of 44 h after estrogen withdrawal. Necrosis was present but was not prominent. Administration of bromocriptine after estrogen withdrawal increased apoptotic counts to nearly...

...Samia Hanna; Seon H. Shin Effects of dopamine and bromocriptine on TRH- or dibutyryladenosine 3’,5’-cyclic monophosphate (dbcAMP)-induced prolactin release from primary cultured rat pituitary cells were studied using a perifusion system. TRH (100 nmol/l) stimulated prolactin release from basal...

... replacement altered the concentrations of αMSH in plasma or DOPAC in the intermediate lobe. Administration of the DA agonist bromocriptine blocked the ability of estrogen to increase plasma prolactin and median eminence DOPAC concentrations. Also, administration of antiserum to rat prolactin blocked...

... that the increases in AP weight following 21 days of E treatment were masking the effects of E on AP cytosolic AR when expressed on a per milligram protein basis. Consequently, we inhibited E-induced AP growth by the simultaneous administration of bromocriptine (BR). BR was administered concurrently with E to female...

.... oGH was ineffective on basal or stimulated in vitro OT release, and neither hormone altered basal or stimulation-induced release of vasopressin from these tissues. Both rPRL and oPRL reversed the inhibitory effect of the D-2 dopamine agonist bromocriptine. Immunoneutralization of circulating PRL...

..., but inhibition of prolactin secretion following administration of the DA agonist bromocriptine blocked the increase in DOPA accumulation in the median eminence of orchidectomized rats; this latter effect was reversed by intracerebroventricular administration of prolactin. On the other hand...

...Gail S. Prins; Andrzej Bartke; Varadaraj Chandrashekar; Jill Reiher; Sherie Hodges; Rita Meyers Nuclear androgen receptors (Arn)were measured in the pituitaries and hypothalami of adult male golden hamsters which had been injected with a long-acting preparation of bromocriptine or had pituitaries...

... hormone (LH) secretion were studied in 5 postmenopausal women either before or after chronic administration of the dopaminergic drug bromocriptine (BCT; 5 mg/day for 30 days). BCT administration did not modify mean plasma LH levels. Before treatment naloxone infusion did not induce any significant...

... agonist, bromocriptine, and a dopamine antagonist, domperidone, as well as a muscarinic cholinergic antagonist, pirenzepine, on the GH response to an analogue of GH-releasing hormone (GHRH) in normal male subjects. GHRH(1–29)NH 2 induced a rise in serum GH that was augmented by bromocriptine, antagonized...

... by measuring the rate of dopamine (DA) synthesis in the median eminence (DOPA accumulation following the administration of a decarboxylase inhibitor). Rats were pretreated with bromocriptine, a dopaminergic agonist, so as to inhibit the release of endogenous PRL from the anterior pituitary, and thereby reduce...

...–6 days with various doses of the following drugs, alone or in combination: haloperidol (a dopamine receptor blocker), reserpine (a catecholamine depleting agent), and bromocriptine (a dopamine receptor agonist). Neurointermediate lobe () homogenates were prepared. Following activation of latent...

... pituitary in the female rat, and the dopaminergic system is sexually differentiated. In order to determine whether or not dopaminergic stimulation might induce sex differences in 3 H-E 2 binding, male and female gonadectomized-adrenalectomized rats were pretreated either with bromocriptine, a dopamine...

... the animals received an intraperitoneal injection of one of the following drugs: apomorphine (0.8 mg/kg, a DA receptor agonist), bromocriptine (8.0 mg/kg, a DA receptor agonist), 0.9% saline (vehicle for apomorphine) or 95% ethanol (vehicle for bromocriptine). Blood sampling was continued for a further 2–2.5...